We, thus, hypothesized that (P)RR inhibition would be an effective way to lower plasma cholesterol and triglycerides concentrations and to reduce the risk for atherosclerosis in familial hypercholesterolemia patients, whose LDLR activity is reduced or diminished, and whose responses to statin is less pronounced than in normal patients (8). The gene discussed is LDLR; the disease is familial hypercholesterolemia.